Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Depressive Disorders: Etiology

Depressive Disorders: Etiology

Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...

Biological Causes of Schizophrenia

Biological Causes of Schizophrenia

Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.

Bipolar Disorder

Bipolar Disorder

Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Thalamic nuclei volumes across psychiatric and neurological disorders: a multi-site magnetic resonance imaging study.

Translational psychiatry·2026

Same author

Identification and evaluation of barriers and facilitators to formal help-seeking for premenstrual symptoms in the UK: a mixed methods approach.

Frontiers in global women's health·2026

Same author

International Consensus Meeting on Infection: Top 10 Evidence-Backed Recommendations and Insights.

The Journal of bone and joint surgery. American volume·2025

Same author

[Mycotic aortic aneurysm-Representative cases : Case series of clinical case examples and the current literature on the treatment options of open surgical resection with prosthesis implantation (OR) and endovascular aortic repair (EVAR)].

Chirurgie (Heidelberg, Germany)·2025

Same author

Improving care experiences for premenstrual symptoms and disorders in the United Kingdom (UK): a mixed-methods approach.

BMC health services research·2025

Same author

Sleep Position Detection for Closed-Loop Treatment of Sleep-Related Breathing Disorders.

IEEE ... International Conference on Rehabilitation Robotics : [proceedings]·2022

Search research articles

Related Experiment Video

Updated: May 29, 2026

Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD

Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD

Published on: October 10, 2012

[Serum-based biomarkers for psychiatric disorders].

S Bahn¹, E Schwarz

¹Department of Chemical Engineering and Biotechnology, Cambridge Centre for Neuropsychiatric Research, University of Cambridge, UK. sb209@cam.ac.uk

|September 13, 2011

Summary

Developing reliable blood biomarkers for schizophrenia faces significant hurdles. Overcoming skepticism and regulatory challenges is key to advancing objective diagnostic tools for psychiatric disorders.

More Related Videos

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)

Published on: March 12, 2020

Related Experiment Videos

Last Updated: May 29, 2026

Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD

Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD

Published on: October 10, 2012

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)

Published on: March 12, 2020

Area of Science:

Psychiatry
Biomarker Science
Neuroscience

Context:

Current diagnostic methods for schizophrenia rely heavily on subjective clinical assessments.
Significant challenges impede the discovery and development of objective, serum-based biomarkers for psychiatric conditions.
There is a notable reluctance among some psychiatrists to accept peripheral molecules as reliable indicators of brain activity.

Purpose:

To review the multifaceted challenges in developing serum-based biomarkers for schizophrenia.
To explore perspectives from psychiatrists, regulatory bodies, and biomarker scientists on biomarker development.
To highlight the critical need for objective diagnostic tools in psychiatric medicine.

Summary:

The development of peripheral biomarkers for schizophrenia is hindered by clinical skepticism and the complexity of reflecting central nervous system changes.
Regulatory agencies emphasize the importance of biomarkers for modernizing drug development, promoting safer and more effective treatments.
The paper examines the creation and market reception of the first molecular blood test for schizophrenia as a case study.

Impact:

Facilitates a deeper understanding of the obstacles in psychiatric biomarker research.
Informs strategies for overcoming clinical and regulatory barriers to biomarker adoption.
Supports the advancement of objective diagnostic tools, potentially improving schizophrenia diagnosis and treatment.